Attached files
| file | filename |
|---|---|
| EX-4.5 - EXHIBIT 4.5 - ARGOS THERAPEUTICS INC | exh_45.htm |
| EX-32.1 - EXHIBIT 32.1 - ARGOS THERAPEUTICS INC | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - ARGOS THERAPEUTICS INC | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - ARGOS THERAPEUTICS INC | exh_311.htm |
| EX-10.44 - EXHIBIT 10.44 - ARGOS THERAPEUTICS INC | exh_1044.htm |
| EX-10.40 - EXHIBIT 10.40 - ARGOS THERAPEUTICS INC | exh_1040.htm |
| EX-10.28 - EXHIBIT 10.28 - ARGOS THERAPEUTICS INC | exh_1028.htm |
| EX-4.3 - EXHIBIT 4.3 - ARGOS THERAPEUTICS INC | exh_43.htm |
| 10-K - FORM 10-K - ARGOS THERAPEUTICS INC | f10k_031617p.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-195223, 333-208055, 333-210522, 333-211403, and 333-213137) and Form S-3 (Nos. 333-204016, 333-211364, 333-212645 and 333-215480) of Argos Therapeutics, Inc. of our report dated March 16, 2017 relating to the financial statements and financial statement schedule, which appears in this Form 10-K.
/s/PricewaterhouseCoopers LLP
Raleigh, North Carolina
March 16, 2017